15 companies chosen for Phase 1

The selection committee has chosen 15 promising projects for Phase I. The projects all focus on developing innovative technologies to dramatically change patient outcomes in a variety of therapeutic areas. All of our project teams are eager to make a significant impact on improving people’s lives.

The aim is now, together with BaseLaunch, Pharma partners, as well as a deep network of experts, further assess each project and help to clearly articulate the near/mid- term milestones (preclinical, regulatory, commercial, and much more) required to further de-risk the science and build the companies. 

The companies are as follows in alphabetical order:


Alibion
Alibion is a pre-clinical stage drug-development company developing the first personalized therapy against Rheumatoid arthritis.

Biotech in stealthmode
Company in stealth mode developing an antibody-based tumor therapy against a first-in-class target in the tumor microenvironment.

 

Biotech in stealthmode
Company in stealth mode developing novel inibitors of the inflammasome.

 

Biotech in stealthmode
Platform for finding new targets and developing novel drugs for solid cancers.

CMET Pharmaceuticals
CMET Pharmaceuticals aims to develop novel therapies for the treatment of metastatic cancers, tailored to target circulating tumour cell clusters.

FoRx
FoRx Therapeutics is developing therapeutics that exploit the presence of DNA replication STRESS in human cancers.

GEBAMO
GEBAMO is bringing CRISPR-Cas12a technology forward.

ImmProfile
ImmProfile is advancing innovative discoveries and solutions in immune oncology.

Innervation Pharmaceuticals
Innervation Pharmaceuticals is a pre-clinical phase biotech. Its patented, solid-phase transfection platform is used for genome-wide screening services and the discovery of genes that boost neuronal regrowth after spinal cord injury.

INSIDER Therapeutics
INSIDER Therapeutics is a preclinical stage spin-off project from University of Zurich. It is developing first-in-class small molecule anticancer therapeutics that modulate the epitranscriptomic code.

ISARNA
ISARNA is a clinical stage Biotech Company, addressing high unmet medical need in Ophthalmology and beyond by developing innovative, targeted, first in class antisense blockbuster therapies for major blinding diseases.

PharmaBiome
PharmaBiome pioneers bacterial mixes as microbiome therapeutics in IBD and oncology based on our mixed-culture technology.

SunRegen
SunRegen develops neuroprotective drugs for neurodegenerative diseases.

Synoesis
Synoesis is developing a first-in-class therapeutic to stop Parkinson’s disease.

TOLREMO
TOLREMO is a cancer drug resistance company. Our resistance-preventing small molecules boost the long-term efficacy of existing cancer drugs to prolong patient survival.

Biotech Office Buildings